Hims & Hers Health Inc (HIMS) Price

Analysts See Upside in CARR and STRA, But Fundamentals Flash Warnings

A StockStory analysis on December 15, 2025, raised concerns about Strategic Education and Carrier Global, citing weakening fundamentals despite analyst price targets suggesting over 26% upside for both.

Investor Interest In HIMS Rises Amid Market Rotation

Investor attention on Hims & Hers Health (HIMS) is increasing as the market shows signs of rotating from AI-related stocks to value sectors like healthcare. While HIMS has outperformed the S&P 500 recently, its near-term earnings forecast poses a significant headwind.

Hims & Hers Expands Personalized Virtual Care Services

Hims & Hers is broadening its telehealth platform by introducing new diagnostic services and specialized hormonal treatments. The company is also entering the Canadian market through a partnership with Livewell, signaling a significant strategic expansion.

Crux Integrates Lilly’s Zepbound On Benefits Platform

Crux has added Eli Lilly's popular obesity drug, Zepbound®, to its employer benefits platform. This move aims to control costs for employers and improve employee access to expensive but high-demand GLP-1 medications, a growing challenge in corporate healthcare.

Lilly's Retatrutide Trial Success Intensifies Obesity Market Race

Eli Lilly reported positive Phase 3 trial results for its drug, retatrutide, demonstrating significant weight loss and osteoarthritis pain relief. This result strengthens its competitive position in the rapidly growing obesity treatment market.

Healthcare Stocks Gain on White House Proposal to Extend ACA Subsidies